Novo Nordisk, the manufacturer of the popular medication, said June 24 the FDA has agreed to review a label extension based on positive phase 3 trial results. The study tested if Ozempic could reduce major kidney disease events among patients with diabetes and chronic kidney disease.
In late May, the Denmark-based drugmaker published the study findings: Ozempic cut the risk of kidney disease-related events by 24%, the risk of a major heart problem by 18% and the risk of death by 20%.
Michael Radin, MD, Novo Nordisk’s executive medical director of diabetes, told Becker’s the study was the “first ever renal outcomes trial with a GLP-1 receptor agonist” at the time.
As of June 25, most GLP-1 medications are solely approved for Type 2 diabetes or chronic weight management. Novo Nordisk’s Wegovy, a weight loss drug, is also indicated for serious heart problems, and Eli Lilly is seeking a sleep apnea approval for Mounjaro, its diabetes drug.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
